There are 2949 resources available
Raising the bar in early TNBC
Presenter: Peter Schmid
Session: F. Hoffmann-La Roche - Advancing Knowledge in Early and Metastatic Triple-Negative Breast Cancer
Resources:
Webcast
Insights from the clinic: Hypothetical eTNBC Patient Scenario(s)
Presenter: Carlos Barrios
Session: F. Hoffmann-La Roche - Advancing Knowledge in Early and Metastatic Triple-Negative Breast Cancer
Resources:
Webcast
New frontiers in metastatic TNBC
Presenter: Rebecca Dent
Session: F. Hoffmann-La Roche - Advancing Knowledge in Early and Metastatic Triple-Negative Breast Cancer
Resources:
Webcast
Insights from the clinic: Hypothetical mTNBC Patient Scenario(s)
Presenter: Carlos Barrios
Session: F. Hoffmann-La Roche - Advancing Knowledge in Early and Metastatic Triple-Negative Breast Cancer
Resources:
Webcast
Looking at the future horizon
Presenter: Sandra Swain
Session: F. Hoffmann-La Roche - Advancing Knowledge in Early and Metastatic Triple-Negative Breast Cancer
Resources:
Webcast
Welcome and introduction
Presenter: Karim Fizazi
Session: F. Hoffmann-La Roche - Reshaping treatment paradigms for GU cancer patients: Perspectives on PI3K/AKT inhibitors in mCRPC and immunotherapy in urothelial cancer
Resources:
Webcast
Improving outcomes with immunotherapy in urothelial cancer: Perspectives on the latest data
Presenter: Enrique Grande
Session: F. Hoffmann-La Roche - Reshaping treatment paradigms for GU cancer patients: Perspectives on PI3K/AKT inhibitors in mCRPC and immunotherapy in urothelial cancer
Resources:
Webcast
The changing landscape of metastatic prostate cancer: Challenges and evolving opportunities
Presenter: Karim Fizazi
Session: F. Hoffmann-La Roche - Reshaping treatment paradigms for GU cancer patients: Perspectives on PI3K/AKT inhibitors in mCRPC and immunotherapy in urothelial cancer
Resources:
Webcast
Targeting AKT: Next breaAKThrough therapies for prostate cancer care?
Presenter: Johann de Bono
Session: F. Hoffmann-La Roche - Reshaping treatment paradigms for GU cancer patients: Perspectives on PI3K/AKT inhibitors in mCRPC and immunotherapy in urothelial cancer
Resources:
Webcast
Exploring molecular heterogeneity in prostate cancer - prevalence and clinical significance
Presenter: Neal Shore
Session: AstraZeneca - PARP inhibitors in the treatment of metastatic castrate resistant prostate cancer
Resources:
Webcast